A Boston biotech betting that the skin's most common conditions deserve real drugs - delivered in a tube, not with a scalpel.
A wordmark on a lab wall in Boston’s Seaport: thirteen people, two kinase inhibitors, and a very specific idea about what your skin needs.
Here is a thing about dermatology that, once you notice it, is hard to un-notice: a great deal of what a dermatologist does all day is physically remove parts of you. They freeze things off, scrape things off, burn things off, cut things off. Seborrheic keratoses - those waxy, stuck-on growths that show up on nearly everyone eventually and are sometimes affectionately called the barnacles of aging - are usually dealt with by a can of liquid nitrogen and a steady hand. There is no pill. There is, for the most part, no cream. There is a procedure and a co-pay.
DermBiont, a clinical-stage biotechnology company headquartered in Boston, looked at that state of affairs and asked a reasonable question: why isn't there a drug for this? The condition affects tens of millions of people. It has a known biology. It is, in the language of the industry, a large and underserved market. And yet the standard of care is essentially carpentry.
The company's answer is a portfolio of what it calls first-in-class targeted topical therapeutics. That phrase is doing a lot of work, so let's unpack it. Targeted means the drugs go after specific molecular machinery - the kinds of enzyme targets you normally hear about in cancer research. Topical means you put it on your skin, where the disease actually lives, rather than swallowing it and dosing your entire body to reach one lesion. First-in-class means nobody has approved a drug quite like it before. Put together, the pitch is precision-oncology-style biology, repackaged into something that feels, roughly, like a fancy moisturizer.
Whether that constitutes a revolution is above my pay grade. What it clearly is, is a bet on an unglamorous truth: some of the best markets are the ones nobody has bothered to build a product for. When an enormous patient population meets an empty pharmacy shelf, that is not a gap so much as an invitation.
DermBiont's lead program, SM-020, is a topical AKT kinase inhibitor for seborrheic keratoses. AKT is a signaling enzyme you would more typically expect to see discussed in a tumor-biology seminar. In Phase 2 studies, the company reported that more than 80% of treated lesions responded and over half cleared completely with a 1.0% gel. A Phase 2b trial was fully enrolled, with topline data expected in 2024. The endpoint is refreshingly concrete: did the growth go away or not.
The second program, SM-030, is a topical PKC-beta inhibitor aimed at melasma and other hyperpigmentation disorders - the stubborn brown patches that have frustrated dermatologists and patients for decades. The incumbent treatment, hydroquinone, is old, cranky, and only sort of works. In a Phase 2a proof-of-concept study, DermBiont said SM-030 showed greater efficacy than 4% hydroquinone with better tolerability. One trial is not a coronation. But in a field this starved for progress, beating the decades-old standard is a genuine signal.
Beyond those two, the company has described earlier-stage work pointed at basal cell carcinomas and skin-cancer prevention, including in patients with Gorlin syndrome, a rare genetic condition that predisposes people to many skin cancers. The through-line is consistent: take a target, aim a small molecule at it, and deliver that molecule precisely where the skin needs it.
The hard part - and this is the part that quietly determines whether any of it works - is delivery. Getting a targeted molecule to sit in the right layer of skin at the right concentration is its own field of science. If DermBiont's real edge turns out to be anything, it is likely to be the boring, essential problem of getting the drug to stay where you put it.
A topical AKT kinase inhibitor gel. In Phase 2, over 80% of lesions responded and more than half cleared completely with the 1.0% formulation. A drug for something usually frozen or scraped off.
A topical PKC-beta inhibitor. In a proof-of-concept trial it outperformed 4% hydroquinone - the field's long-standing standard - with better tolerability and safety.
Topical work aimed at basal cell carcinomas and prevention, including for patients with Gorlin syndrome, a rare disorder driving many skin cancers.
DermBiont was founded in 2017 and is led by Karl Beutner, M.D., Ph.D., its CEO and Chief Medical Officer. His resume is the kind venture investors like to see: he was previously Chief Medical Officer at Anacor Pharmaceuticals, later acquired by Pfizer, and at Dow Pharmaceutical Sciences, later acquired by Valeant. That is two dermatology companies taken far enough to get bought. Domain scar tissue is underrated, and Beutner has it.
Alongside him, co-founder Nichola Eliovits serves as Chief Financial Officer, with Max N. Dawson as Chief Operating Officer. The board includes Daniel Yadegar, M.D. of Double Point Ventures, Steven Basta (CEO of Phathom Pharmaceuticals), and Wilder Ramsey of Toba Capital - a mix of operators and investors keeping a small team pointed in one direction.
The financing allows us to accelerate the development of our pipeline of novel topical therapeutics.
DermBiont did not raise one enormous round and hope. It stacked capital in step with milestones - a pattern that helps science companies survive the long timelines their work demands. Along the way it bought Chromaderm in 2021 to broaden its hyperpigmentation pipeline, proving that buy-versus-build is a live question even for a company of thirteen.
| Round | Amount | Date | Notable Investors |
|---|---|---|---|
| Series A | $8M | 2019 | Civilization Ventures, Viking Global |
| Series A2 | $28M | Dec 2021 | Viking Global, Civilization Ventures, Olive Tree Capital |
| Series B (first close) | $35.2M | Oct 2023 | Double Point Ventures (lead), Viking Global, Olive Tree |
The 2023 Series B combined a $27.1M first close with $8.1M in converting notes. Total funding across rounds is reported at roughly $79M+.
Karl Beutner and co-founders launch the company to develop targeted topical therapeutics for skin disease.
Backed by Civilization Ventures and Viking Global to treat the root cause of skin diseases.
Raises Series A2 funding and acquires Chromaderm to expand its hyperpigmentation pipeline.
Double Point Ventures leads a Series B to accelerate SM-020 and SM-030.
Details progress on topical therapeutics for seborrheic keratoses, basal cell carcinomas, and melasma.
DermBiont is a clinical-stage biotechnology company developing first-in-class targeted topical drugs to treat the root cause of common skin diseases, including seborrheic keratoses, melasma, and certain skin cancers.
Its two lead candidates are SM-020, a topical AKT kinase inhibitor for seborrheic keratoses, and SM-030, a topical PKC-beta inhibitor for melasma and hyperpigmentation.
DermBiont was founded in 2017. Its CEO and Chief Medical Officer is Karl Beutner, M.D., Ph.D., a dermatology drug-development veteran, alongside co-founder and CFO Nichola Eliovits.
DermBiont has raised roughly $79 million or more across several rounds, including a $35.2M Series B in 2023 led by Double Point Ventures, with earlier Series A and Series A2 rounds.
DermBiont is headquartered in Boston, Massachusetts, and operates as a lean, science-focused team of around 13 people.
Profile compiled from public sources including DermBiont.com, BioSpace, BusinessWire, Pulse 2.0, Microbiome Times, and citybiz. Trial results and figures are as reported by the company and press; treat forward-looking pipeline details as approximate.